CL2016001100A1 - Formulación compuesta que comprende gránulos húmedos de tadalafilo y lactosa y/o manitol y una mezcla de amlodipina en una cantidad de 6-16 partes de tadalafilo y amlodipina por 100 partes de la composición; método para prepararla; uso para tratar una enfermedad cardiovascular, disfunción eréctil o una combinación de ellas. - Google Patents

Formulación compuesta que comprende gránulos húmedos de tadalafilo y lactosa y/o manitol y una mezcla de amlodipina en una cantidad de 6-16 partes de tadalafilo y amlodipina por 100 partes de la composición; método para prepararla; uso para tratar una enfermedad cardiovascular, disfunción eréctil o una combinación de ellas.

Info

Publication number
CL2016001100A1
CL2016001100A1 CL2016001100A CL2016001100A CL2016001100A1 CL 2016001100 A1 CL2016001100 A1 CL 2016001100A1 CL 2016001100 A CL2016001100 A CL 2016001100A CL 2016001100 A CL2016001100 A CL 2016001100A CL 2016001100 A1 CL2016001100 A1 CL 2016001100A1
Authority
CL
Chile
Prior art keywords
parts
tadalafil
amlodipine
lactose
prepare
Prior art date
Application number
CL2016001100A
Other languages
English (en)
Inventor
Yong Ii Kim
Jae Hyun Park
Jong Soo Woo
Jin Cheul Kim
Jae Ho Kim
Caleb Hyungmin Park
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2016001100A1 publication Critical patent/CL2016001100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

FORMULACIÓN COMPUESTA QUE COMPRENDE GRÁNULOS HÚMEDOS DE TADALAFILO Y LACTOSA Y/O MANITOL Y UNA MEZCLA DE AMLODIPINA EN UNA CANTIDAD DE 6-16 PARTES DE TADALAFILO Y AMLODIPINA POR 100 PARTES DE LA COMPOSICIÓN; MÉTODO PARA PREPARARLA; USO PARA TRATAR UNA ENFERMEDAD CARDIOVASCULAR, DISFUNCIÓN ERÉCTIL O UNA COMBINACIÓN DE ELLAS.
CL2016001100A 2013-11-15 2016-05-06 Formulación compuesta que comprende gránulos húmedos de tadalafilo y lactosa y/o manitol y una mezcla de amlodipina en una cantidad de 6-16 partes de tadalafilo y amlodipina por 100 partes de la composición; método para prepararla; uso para tratar una enfermedad cardiovascular, disfunción eréctil o una combinación de ellas. CL2016001100A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130139334 2013-11-15
KR1020140096022A KR20150056443A (ko) 2013-11-15 2014-07-28 타다라필 및 암로디핀을 포함하는 복합제제

Publications (1)

Publication Number Publication Date
CL2016001100A1 true CL2016001100A1 (es) 2016-11-11

Family

ID=53391753

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001100A CL2016001100A1 (es) 2013-11-15 2016-05-06 Formulación compuesta que comprende gránulos húmedos de tadalafilo y lactosa y/o manitol y una mezcla de amlodipina en una cantidad de 6-16 partes de tadalafilo y amlodipina por 100 partes de la composición; método para prepararla; uso para tratar una enfermedad cardiovascular, disfunción eréctil o una combinación de ellas.

Country Status (14)

Country Link
US (1) US20160263040A1 (es)
EP (1) EP3068380A4 (es)
JP (1) JP2016539934A (es)
KR (3) KR101663238B1 (es)
CN (1) CN105744930A (es)
AR (1) AR098415A1 (es)
AU (1) AU2014349417A1 (es)
CA (1) CA2927720A1 (es)
CL (1) CL2016001100A1 (es)
HK (1) HK1221665A1 (es)
MX (1) MX2016006292A (es)
PH (1) PH12016500865A1 (es)
RU (1) RU2016117186A (es)
TW (1) TW201605441A (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170113459A (ko) * 2016-03-31 2017-10-12 한미약품 주식회사 타다라필 및 암로디핀 함유 고형 복합제제
JP2019510071A (ja) * 2016-03-31 2019-04-11 ハンミ ファーマシューティカルズ カンパニー リミテッド 安定性及び溶出率が改善されたタダラフィル含有及びタムスロシン含有のカプセル複合製剤
US10350171B2 (en) * 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
JP7334144B2 (ja) * 2018-03-16 2023-08-28 日本新薬株式会社 口腔内崩壊錠
CN109528675B (zh) * 2018-12-31 2020-12-22 杭州康本医药科技有限公司 一种他达拉非肠溶片剂及其制备方法
KR102195162B1 (ko) 2019-01-30 2020-12-24 단국대학교 천안캠퍼스 산학협력단 타다라필 함유 고체분산체 및 이의 제조방법
CN110638768B (zh) * 2019-10-25 2024-04-16 株洲千金药业股份有限公司 一种治疗男性勃起功能障碍药物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001632A3 (en) 1999-04-30 2001-12-28 Lilly Icos Llc Wilmington Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
KR20100012867A (ko) * 2007-04-25 2010-02-08 테바 파마슈티컬 인더스트리즈 리미티드 타다라필을 포함하는 고체 제형
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
US20100316711A1 (en) * 2007-10-25 2010-12-16 Bayer Yakuhin ,Ltd. Nifedipine containing opress coated tablet and method of preparing same
CA2749903C (en) * 2009-01-23 2016-09-06 Jae Hyun Park Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
EP2672959A1 (en) * 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant

Also Published As

Publication number Publication date
US20160263040A1 (en) 2016-09-15
KR101665641B1 (ko) 2016-10-13
CA2927720A1 (en) 2015-05-21
CN105744930A (zh) 2016-07-06
AR098415A1 (es) 2016-05-26
AU2014349417A1 (en) 2016-05-05
KR20150056461A (ko) 2015-05-26
EP3068380A4 (en) 2017-06-28
PH12016500865A1 (en) 2016-06-20
KR20150056444A (ko) 2015-05-26
JP2016539934A (ja) 2016-12-22
EP3068380A1 (en) 2016-09-21
KR20150056443A (ko) 2015-05-26
HK1221665A1 (zh) 2017-06-09
TW201605441A (zh) 2016-02-16
RU2016117186A (ru) 2017-12-18
KR101663238B1 (ko) 2016-10-14
MX2016006292A (es) 2016-09-08

Similar Documents

Publication Publication Date Title
CL2016001100A1 (es) Formulación compuesta que comprende gránulos húmedos de tadalafilo y lactosa y/o manitol y una mezcla de amlodipina en una cantidad de 6-16 partes de tadalafilo y amlodipina por 100 partes de la composición; método para prepararla; uso para tratar una enfermedad cardiovascular, disfunción eréctil o una combinación de ellas.
CL2019000473A1 (es) Compuestos de pirrolizina sustituida y usos de los mismos.
HK1251901A1 (zh) 烯基取代的2，5-哌嗪二酮和其在組合物中用於向個體或細胞遞送藥劑的用途
CL2015002860A1 (es) Antagonistas de la alfa-v-beta-6 integrina
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
BR112018005892A2 (pt) composições para higiene bucal e métodos de uso.
CL2015001055A1 (es) Composiciones para lavado de ropa; y uso de dicha composicion.
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
AR108507A1 (es) Un dispositivo de vaporización, método de uso del dispositivo, un estuche de carga, un kit y un ensamblaje de vibración
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112018005753A2 (pt) composições para higiene bucal e métodos de uso.
BR112016025910A2 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
PE20151759A1 (es) Imidazopiridazinas sustituidas
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
ECSP16058769A (es) Composicion para la administracion oral de agente bioactivos
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112014003040A2 (pt) mistura de polímero em uma forma sólida ou aquosa, composição, e, uso de misturas de polímero.
UY35835A (es) Anticuerpos específicos para FcRn.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
CL2016000998A1 (es) Composición herbaria, procedimiento para su preparación y uso de la misma